Literature DB >> 18480013

Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

Patricia R Slev1, Sonia L La'ulu, William L Roberts.   

Abstract

Serum prostate-specific antigen (PSA) assays differ in calibration and response to different PSA forms. We examined intermethod differences in total PSA (tPSA) and free PSA (fPSA) measurements. We tested 157 samples with tPSA concentrations of 2 to 10 ng/mL (2-10 microg/L) using 6 PSA/fPSA method pairs and 1 tPSA method: ADVIA Centaur (complexed and total; Siemens Diagnostics, Tarrytown, NY), ARCHITECT i 2000(SR) (Abbott Diagnostics, Abbott Park, IL), AxSYM (Abbott Diagnostics), IMMULITE 2000 (Siemens Diagnostics), Modular E170 (Roche Diagnostics, Indianapolis, IN), UniCel DxI 800 (Beckman Coulter, Brea, CA), and VITROS ECi (tPSA only; Ortho-Clinical Diagnostics, Raritan, NJ). Regression analysis was performed for PSA, fPSA, and percentage of fPSA with the ARCHITECT i 2000(SR) comparison method. Differences between test and comparison methods were estimated at 2.5, 4.0, and 10.0 ng/mL (2.5, 4.0, and 10.0 microg/L) for tPSA and 15%, 20%, and 25% for percentage of fPSA. Relative differences were more than 10% at 4.0 ng/mL (4.0 microg/L) tPSA for the Centaur, IMMULITE, ECi, and DxI methods. At 20% fPSA, the relative difference was more than 10% for all methods except the AxSYM. Additional harmonization is needed for tPSA and fPSA methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480013     DOI: 10.1309/JYBPMFNUF6EYY9TB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Prostate cancer: WHO standardization of PSA tests: clinical consequences.

Authors:  Carsten Stephan
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

2.  Variability of assay methods for total and free PSA after WHO standardization.

Authors:  L Foj; X Filella; J Alcover; J M Augé; J M Escudero; R Molina
Journal:  Tumour Biol       Date:  2013-10-04

3.  Prostate cancer screening: Canadian guidelines 2011.

Authors:  Jonathan I Izawa; Laurence Klotz; D Robert Siemens; Wassim Kassouf; Alan So; John Jordan; Michael Chetner; Alla E Iansavichene
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

4.  Prostate-specific antigen (PSA) screening: has the pendulum swung too far?

Authors:  Jason M Phillips; E David Crawford
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

Review 5.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 6.  Active surveillance in prostate cancer: the need to standardize.

Authors:  Xavier Filella; Juan Alcover; Rafael Molina
Journal:  Tumour Biol       Date:  2011-05-28

Review 7.  Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.

Authors:  George Botchorishvili; Mika P Matikainen; Hans Lilja
Journal:  Curr Opin Urol       Date:  2009-05       Impact factor: 2.309

8.  Comparison of self-reported female condom failure and biomarker-confirmed semen exposure.

Authors:  Terri L Walsh; Margaret C Snead; Breione J St Claire; Jill L Schwartz; Christine K Mauck; Ron G Frezieres; Diana L Blithe; David F Archer; Kurt T Barnhart; Jeffrey T Jensen; Anita L Nelson; Michael A Thomas; Livia S Wan; Mark A Weaver
Journal:  Contraception       Date:  2019-08-02       Impact factor: 3.375

9.  Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.

Authors:  Manuel M Garrido; José C Marta; Ruy M Ribeiro; Luís C Pinheiro; Stefan Holdenrieder; João T Guimarães
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

10.  Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases.

Authors:  In Seok Yoon; Tae Young Shin; Sun Il Kim; Seong Kon Park; Hyun Ik Jang; Jong Bo Choi; Hyun Soo Ahn; Young Soo Kim; Se Joong Kim
Journal:  Korean J Urol       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.